19 June 2013
Keywords: kissei, licenses, kad-1229, servier, japan, licensed, its
Article | 27 November 1995
- Kissei of Japan has licensed its novel diabetes drug KAD-1229 to
Servier of France for development and commercialization in Europe. ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
27 November 1995
4 December 1995
18 June 2013
© 2013 thepharmaletter.com